BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15846492)

  • 1. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice.
    Sabel MS; Hess SD; Egilmez NK; Conway TF; Chen FA; Bankert RB
    Cancer Immunol Immunother; 2005 Oct; 54(10):944-52. PubMed ID: 15846492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
    Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
    Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of murine Lyme borreliosis by interruption of the B7/CD28 T-cell costimulatory pathway.
    Shanafelt MC; Kang I; Barthold SW; Bockenstedt LK
    Infect Immun; 1998 Jan; 66(1):266-71. PubMed ID: 9423867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
    Mandelbrot DA; McAdam AJ; Sharpe AH
    J Exp Med; 1999 Jan; 189(2):435-40. PubMed ID: 9892625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
    LaBelle JL; Hanke CA; Blazar BR; Truitt RL
    Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of costimulatory molecules on dendritic cells: implications for tolerance induction.
    Luke PP; Thomson AW
    Transplant Proc; 2001; 33(1-2):507-8. PubMed ID: 11266929
    [No Abstract]   [Full Text] [Related]  

  • 8. CTLA-4 is required for the induction of high dose oral tolerance.
    Samoilova EB; Horton JL; Zhang H; Khoury SJ; Weiner HL; Chen Y
    Int Immunol; 1998 Apr; 10(4):491-8. PubMed ID: 9620605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
    Pistillo MP; Tazzari PL; Bonifazi F; Bandini G; Kato T; Matsui T; Nishioka K; Conte R; Ferrara GB
    Transplantation; 2002 Apr; 73(8):1295-302. PubMed ID: 11981425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
    Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
    J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
    Wu Y; Guo Y; Huang A; Zheng P; Liu Y
    J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease.
    Chang TT; Kuchroo VK; Sharpe AH
    Curr Dir Autoimmun; 2002; 5():113-30. PubMed ID: 11826754
    [No Abstract]   [Full Text] [Related]  

  • 15. CD28-independent costimulation of T cells in alloimmune responses.
    Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
    J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of rat to mouse cardiac xenografts with prolonged blockade of CD28-B7 interaction combined with peritransplant T-cell depletion.
    Rehman A; Tu Y; Arima T; Linsley PS; Flye MW
    Surgery; 1996 Aug; 120(2):205-12. PubMed ID: 8751584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
    Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
    Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulatory regulation of T cell function.
    Chambers CA; Allison JP
    Curr Opin Cell Biol; 1999 Apr; 11(2):203-10. PubMed ID: 10209159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expanding world of co-stimulation: the two-signal model revisited.
    Chambers CA
    Trends Immunol; 2001 Apr; 22(4):217-23. PubMed ID: 11274928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
    Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
    Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.